| Methods |
Single centre, double‐blind, placebo‐controlled
Randomisation by sealed numbered opaque envelope
ITT analysis |
| Participants |
Canada
23 patients: T: 11, C: 12
Mean age: 63 years
Males: T: 5, C: 6
Inclusion: completed cerebrovascular accidents
100% CT pre‐entry
Enrolment within 48 hours of ictus
5 patients enrolled > 48 hours |
| Interventions |
T: PGI2 ("Cycloprostin", Upjohn Co, USA) 5 daily 8‐hour consecutive infusions weaned up from 2 to 10 mg/kg/min and tapered over last hour
C: sterile diluent buffer (NaCl 0.147 w/v, glycine 0.188 w/v, NaOH, pH 10.5 +/‐ 0.3)
Rx: 5 days |
| Outcomes |
Death at 5 days and 1, 2, and 4 weeks. (Neurological impairment rating at 5 days, and 1, 2, and 4 weeks; CT and PET at 5 to 9 days.)
Method for measuring BP not known |
| Notes |
Ex: coma, complicating neurological conditions, heparin, malignant hypertension, uncontrolled DM, heart attack within 2 months, recent surgery
Mixture of data used |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Adequate sequence generation? |
Low risk |
Randomisation by sealed numbered opaque envelope |
| Allocation concealment? |
Unclear risk |
Unclear from the publication |
| Blinding? |
Low risk |
Probably done |
| Completeness of follow‐up |
Unclear risk |
Unclear from the publication |
